TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...
Copenhagen, Denmark, 7 June2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.
Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast, Bharuch district, GujaratEmployees and communities work together to conserve...
The line-up includes two new para-athletes – Indonesian para cyclist Muhammad Fadli Imamuddin and Malaysian para-athletics sprinter Muhammad Ammar Aiman Nor Azmi – alongside...
Chinese model targets local issues, improves livelihoods in remote Laos settlementLUANG PRABANG, Laos, June 4, 2026 /PRNewswire/ -- A report from Chinadaily.com.cnTo mark the...
- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...
Volunteers will assemble hygiene kits for K–12 school, college and university food pantries across four Colorado cities, addressing a critical gap left by federal...
Los Angeles Dianetics volunteers joined a global outreach offering Dianetics and free stress tests to raise awareness and close out Mental Health Awareness
QUEBEC CITY, June 03, 2026 (GLOBE NEWSWIRE) -- Media is invited to attend MADD Canada’s Quebec Provincial Memorial ceremony in honour of those who have been killed in alcohol and/or drug-related crashes. This year, three more names have been added to the Memorial: Marie-Jade Kuncer, Jolyane Potvin, and Derek Godin-Rioux, raising the total number of victims to 61.
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
New research projects focus on behavioral safety, crash prevention and passive safetyANN ARBOR, Mich., June 2, 2026 /PRNewswire/ -- Before joining Toyota's Collaborative Safety Research Center (CSRC), Zhaonan Sun spent years...
The Foundation for America's Public Lands and Polaris have joined forces; Award first round of grants to seven projects across four states WASHINGTON, June...
HANOI, Vietnam, Aug. 15, 2025 /PRNewswire/ -- Vantage Foundation has strengthened its commitment to child protection through Blue Dragon Children's Foundation in Vietnam. The...